NOTICES

Week of October 26, 2015

- NIH Research Involving Introduction of Human Pluripotent Cells into Non-Human Vertebrate Animal Pre-Gastrulation Embryos (NOT-OD-15-158) National Institutes of Health
- Precision Medicine Initiative Cohort Program Recommendations Issued and Accepted (NOT-OD-15-159) National Institutes of Health
- Notice of Participation of the Office of Research Infrastructure Programs in PA-14-154 "Early Stage Development of Technologies in Biomedical Computing, Informatics, and Big Data Science (R43/R44)" (NOT-OD-15-161) Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs
- Notice to Discontinue NCI Supplements to the Continuing Umbrella of Research Experiences (CURE): P30s, T32s, K12s and R25s (NOT-CA-15-034) National Cancer Institute
- Notice of Participation of the National Institute of Nursing Research (NINR) in PAR-15-349 "Health Disparities and Alzheimer's Disease (R01)" (NOT-NR-15-004) National Institute of Nursing Research
- Notice Announcing FAQs Page for PAR-14-315 "Testing Interventions for Health-Enhancing Physical Activity (R01) and PAR-14-321 Developing Interventions for Health-Enhancing Physical Activity (R21/R33) (NOT-OD-15-162) Office of Disease Prevention
- Request for Information (RFI): Soliciting Input for the National Center for Advancing Translational Sciences (NCATS) Strategic Planning Process (NOT-TR-16-002) National Center for Advancing Translational Sciences
- Notice of Participation of the Office of Research Infrastructure Programs in PA-15-258 "Administrative Supplements for Research on Dietary Supplements (Admin Supp)" (NOT-OD-16-016) Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs
- Notice of Intent to Publish a Funding Opportunity Announcement for NCI Supplements to the Continuing Umbrella of Research Experiences (Administrative Supplements to T32 and K12) (NOT-CA-15-036) National Cancer Institute
- Notice of Intent to Publish a Funding Opportunity Announcement for Innovative Molecular and Cellular Analysis Technologies for Cancer Research (R21) (NOT-CA-15-037) National Cancer Institute
- Notice of Intent to Publish a Funding Opportunity Announcement for Advanced Development and Validation of Emerging Molecular Analysis Technologies for Cancer Research (R33) (NOT-CA-15-038) National Cancer Institute
- Notice of Intent to Publish a Funding Opportunity Announcement for Innovative Technologies for Cancer-Relevant Biospecimen Science (R21) (NOT-CA-15-039) National Cancer Institute
- Notice of Intent to Publish a Funding Opportunity Announcement for Advanced Development and Validation of Technologies for Cancer-Relevant Biospecimen Science (R33) (NOT-CA-15-040) National Cancer Institute
- Notice of Correction PAR-13-386 "Cancer Center Support Grants (CCSGs) for NCI-designated Cancer Centers (P30)" to Delete a Requirement to Group Shared Resources (NOT-CA-15-043) National Cancer Institute
- Notice of Pre-application Webinar for PAR-15-286 and PAR-15-287 Opportunities for Collaborative Research at the NIH Clinical Center (X02 and U01)


**REQUEST FOR APPLICATIONS**

**TITLE: Household Air Pollution (HAP) Health Outcomes Trial (UM1)**

(RFA-HL-16-012)

**SPONSOR:** National Heart, Lung, and Blood Institute, John E. Fogarty International Center, National Cancer Institute Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institute of Environmental Health Sciences, The Common Fund/Office of Strategic Coordination

**Synopsis:** This funding opportunity announcement (FOA) seeks applications from institutions/organizations for a cooperative agreement research grant (UM1) to conduct a clinical trial across three or more Low and Middle Income Country (LMIC) settings to test improved stove and fuel interventions on health outcomes in exposed populations. In addition, each application must include a biomarker center element for the development and validation of clinical, physiological, chemical, biochemical and/or microbiological markers of: a) exposure, and b) pathophysiological responses.

Application Receipt Date(s): January 19, 2016

**TITLE: Phase II Innovation Award for Mechanistic Studies to Optimize Mind and Body Interventions in NCCIH High Priority Research Topics (R33)**

(RFA-AT-16-006)

**SPONSOR:** National Center for Complementary and Integrative Health

Application Receipt Date(s): January 15, 2016

**TITLE: Limited Competition: Knockout Mouse Phenotyping Project Database (UM1)**

(RFA-RM-15-016)

**SPONSOR:** NIH Roadmap Initiatives, National Cancer Institute, National Eye Institute, National Human Genome Research Institute, National Heart, Lung, and Blood Institute, National Institute on Aging, National Institute on Alcohol Abuse and Alcoholism, National Institute of Allergy and Infectious Diseases, National Institute of Arthritis and Musculoskeletal and Skin Diseases, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institute on Drug Abuse, National Institute on Deafness and Other Communication Disorders, National Institute of Dental and Craniofacial Research, National Institute of Diabetes and Digestive and Kidney Diseases, National Institute of Environmental Health Sciences, National Institute of General Medical Sciences, National Institute of Neurological Disorders and Stroke, Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs, Office of Research on Women's Health

**Synopsis:** This Notice announces modifications to align with standard biographical sketch format that became effective May 25, 2015 (see NOT-OD-15-032). The new standard biographical sketch format will be adopted and the one page attachment for describing the Program Director/Principal Investigator's (PD/PD's) single most significant publication or research accomplishment will no longer be used. Additionally, the requirement for the applicant to include a statement indicating his/her commitment to devote a minimum of 25% research effort to the New Innovator Award has been moved to the Research Strategy section.

Application Receipt Date(s): December 09, 2015

**TITLE: Limited Competition: Knockout Mouse Production and Phenotyping Project (UM1)**

(RFA-RM-15-017)

**Sponsor:** NIH Roadmap Initiatives, National Cancer Institute, National Eye Institute, National Human Genome Research Institute, National Heart, Lung, and Blood Institute, National Institute on Aging, National Institute on Alcohol Abuse and Alcoholism, National Institute of Allergy and Infectious Diseases, National Institute of Arthritis and Musculoskeletal and Skin Diseases, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institute on Drug Abuse, National Institute on Deafness and Other Communication Disorders, National Institute of Dental and Craniofacial Research, National Institute of Diabetes and Digestive and Kidney Diseases, National Institute of Environmental Health Sciences, National Institute of Neurological Disorders and Stroke, Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs, Office of Research on Women's Health

**Synopsis:** The recent breakthroughs in CRISPR/Cas9 technology make the mouse an even more cost effective model system and will drive technology of mouse production. The goal of this FOA is to support high-throughput broad based phenotyping of approximately 600 null-mutant mouse lines per year, with an overall goal of 3,000 lines for this five-year project period of the Knockout Mouse Phenotyping Program (KOMP2).

Application Receipt Date(s): Multiple dates, see announcement.
**TITLE:** Cancer Detection, Diagnosis, and Treatment Technologies for Global Health (UG3/UH3)  
(RFA-CA-15-024)  
**SPONSOR:** National Cancer Institute, National Institute of Biomedical Imaging and Bioengineering  
**Synopsis:** This Funding Opportunity Announcement (FOA) supports the development of cancer-relevant technologies suitable for use in low- and middle-income countries (LMICs). Specifically, the FOA solicits applications for projects to adapt, apply, and validate existing or emerging technologies into a new generation of user-friendly, low-cost technologies for imaging, detecting, diagnosing, preventing, and/or treating cancers in humans living in LMICs. UG3 applicants should have a working assay or device prototype (not necessarily already capable of cancer applications). The initial UG3 exploratory phase will be a feasibility study to demonstrate technical functionality and clinical potential for use of the device or assay in LMIC settings by meeting specific performance milestones. UG3 projects that have met their milestones will be administratively considered by NCI and prioritized for transition to the UH3 validation phase. UH3 awards will support improvements and validations of the technologies in the LMIC settings. Projects proposed in response to this FOA will require multidisciplinary efforts to succeed; therefore, all applicant teams must include expertise in engineering/assay/treatment development, oncology, global healthcare delivery, and business development. Investigators responding to this FOA must address both the UG3 and UH3 phases.  
**Application Receipt Date(s):** February 09, 2016

**TITLE:** Collaborative Aging (in Place) Research Using Technology (CART) (U2C)  
(RFA-AG-16-021)  
**SPONSOR:** National Institute on Aging, National Cancer Institute, National Institute of Biomedical Imaging and Bioengineering, National Institute of Neurological Disorders and Stroke, National Institute of Nursing Research, Office of Behavioral and Social Science Research.  
**Synopsis:** The purpose of this, Inter-Agency Funding Opportunity Announcement (FOA) is to develop and validate the infrastructure for rapid and effective conduct of future research utilizing technology to facilitate aging in place, with a special emphasis on people from underrepresented groups. This FOA is designed to support Collaborative Aging (in Place) Research Using Technology (CART) by developing and validating a research infrastructure that has the capacity to integrate data across different projects, incorporates existing technologies, and can accommodate future technologies, designed to assess and intervene across a variety of observational and clinical research studies and settings, and for a range of measures, diseases and populations. The infrastructure development will include a demonstration project, to test feasibility for operating on a larger scale. The infrastructure and demonstration project accomplished by this FOA (Phase I) will serve as the foundation for the subsequent large-scale development project for technology research to help reduce hospitalizations, emergency room visits, and admissions to a nursing home for the older population (Phase II). Phase I is designed to be both disease and technology agnostic. Successful multidisciplinary applicants with strong partnerships in engineering, computer science, health and medical research (both public and private sector) are encouraged to apply.  
**Application Receipt Date(s):** January 12, 2016

**TITLE:** Genomic Data Analysis Network: Processing Genomic Data Center (U24)  
(RFA-CA-15-018)  
**SPONSOR:** National Cancer Institute  
**Synopsis:** This FOA solicits applications for a Processing Genomic Data Center that will be a part of the Genomic Data Analysis Network. The network will also include other types of Genome Data Analysis Centers (GDACs) to be supported under companion FOAs, RFA-CA-15-019 and RFA-CA-15-020. The collective goal for all types of GDACs is to enable the cancer research community to develop tools and strategies to analyze the data generated from large-scale genomics projects and support the scientific community at-large in their investigation of the results. The **GDAC to be supported under this FOA** will be expected to focus on the integration and analysis of data generated by the GCCs and other project participants, development of innovative bioinformatic and computational tools and the implementation of advanced bioinformatic analyses including, but not limited to: systems biology approaches to discovery, pathway analysis models, integrative data analysis methods with accompanying visualization tools to identify complex genomic changes, and integrated cancer biology and translational discovery models that will increase our understanding of cancer as a disease process.  
**Application Receipt Date(s):** January 27, 2016

**TITLE:** Genomic Data Analysis Network: Visualization Genomic Data Center (U24)  
(RFA-CA-15-019)  
**SPONSOR:** National Cancer Institute  
**Synopsis:** This FOA solicits applications for a Visualization Genomic Data Center that will be a part of the Genomic Data Analysis Network. The network will also include other types of Genome Data Analysis Centers (GDACs) to be supported under companion FOAs, RFA-CA-15-018 and RFA-CA-15-020. The collective goal for all types of GDACs is to enable the cancer research community to develop tools and strategies to analyze the data generated from large-scale genomics projects and support the scientific community at-large in their investigation of the results. The **GDAC to be supported under this FOA** will be expected to focus on the development of visualization tools to facilitate the integration and analysis of data generated by the GCCs and other project participants, development of innovative bioinformatic and computational tools and the implementation of advanced bioinformatic analyses including, but not limited to: systems biology approaches to discovery, pathway analysis models, integrative data analysis methods with accompanying visualization tools to identify complex genomic changes, and integrated cancer biology and translational discovery models that will increase our understanding of cancer as a disease process.
• **TITLE:** Genomic Data Analysis Network: Specialized Genomic Data Center (U24)  
  **SPONSOR:** National Cancer Institute  
  **Synopsis:** This FOA solicits applications for a Specialized Genomic Data Center that will be a part of the Genomic Data Analysis Network. The network will also include other types of Genome Data Analysis Centers (GDACs) to be supported under companion FOAs, RFA-CA-15-018 and RFA-CA-15-019. The collective goal for all types of GDACs is to enable the cancer research community to develop tools and strategies to analyze the data generated from large-scale genomics projects and support the scientific community at-large in their investigation of the results. The GDACs to be supported under this FOA will be expected to focus on the intensive analysis of discrete sets of genomic platforms (core competencies) to facilitate the integration and analysis of data generated by the GCCs and other project participants, deployment of innovative bioinformatic and computational tools and the implementation of advanced bioinformatic analyses including, but not limited to: systems biology approaches to discovery, pathway analysis models, integrative data analysis methods with accompanying visualization tools to identify complex genomic changes, and integrated cancer biology and translational discovery models that will increase our understanding of cancer as a disease process.  
  Application Receipt Date(s): January 27, 2016

• **TITLE:** Pre-clinical Research Based on Existing Repurposing Tools (R21)  
  **SPONSOR:** National Center for Advancing Translational Sciences  
  Application Receipt Date(s): January 13, 2016

**PROGRAM ANNOUNCEMENTS**

• **TITLE:** Research Supplements to Promote Re-Entry into Biomedical and Behavioral Research Careers (Admin Supp)  
  **SPONSOR:** National Institutes of Health, John E. Fogarty International Center, National Center for Advancing Translational Sciences, National Center for Complementary and Integrative Health, National Cancer Institute, National Eye Institute, National Human Genome Research Institute, National Heart, Lung, and Blood Institute, National Institute on Aging, National Institute on Alcohol Abuse and Alcoholism, National Institute of Allergy and Infectious Diseases, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institute of Biomedical Imaging and Bioengineering, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institute on Drug Abuse, National Institute on Deafness and Other Communication Disorders, National Institute of Dental and Craniofacial Research, National Institute of Diabetes and Digestive and Kidney Diseases, National Institute of Environmental Health Sciences, National Institute of General Medical Sciences, National Institute of Mental Health, National Institute on Minority Health and Health Disparities, National Institute of Neurological Disorders and Stroke, National Institute of Nursing Research, National Library of Medicine, Office of Dietary Supplements, Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs, Office of Research on Women's Health, The Common Fund/Office of Strategic Coordination  
  **Synopsis:** The Office of Research on Women's Health (ORWH) and participating Institutes and Centers (ICs) of the National Institutes of Health (NIH) announce the continuation of the program for administrative supplements to research grants to support individuals with high potential to re-enter an active research career after an interruption for family responsibilities or other qualifying circumstances. The purpose of these supplements is to encourage such individuals to re-enter research careers within the missions of all the program areas of NIH. This program will provide administrative supplements to existing NIH research grants for the purpose of supporting full-time or part-time research by these individuals to update their existing research skills and knowledge.  
  Application Receipt/Submission Date(s): Due dates may vary by awarding IC. See Table of IC-Specific Information, Requirements and Staff Contacts for more details.

• **TITLE:** Research Supplements to Promote Diversity in Health Related Research (Admin Supp)  
  **SPONSOR:** National Institutes of Health, John E. Fogarty International Center, National Center for Advancing Translational Sciences, National Center for Complementary and Integrative Health, National Cancer Institute, National Eye Institute, National Human Genome Research Institute, National Heart, Lung, and Blood Institute, National Institute on Aging, National Institute on Alcohol Abuse and Alcoholism, National Institute of Allergy and Infectious Diseases, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institute of Biomedical Imaging and Bioengineering, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institute on Drug Abuse, National Institute on Deafness and Other Communication Disorders, National Institute of Dental and Craniofacial Research, National Institute of Diabetes and Digestive and Kidney Diseases, National Institute of Environmental Health Sciences, National Institute of General Medical Sciences, National Institute of Mental Health, National Institute on Minority Health and Health Disparities, National Institute of Neurological Disorders and Stroke,
National Institute of Nursing Research, National Library of Medicine, Office of Dietary Supplements, Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs, The Common Fund/Office of Strategic Coordination

Synopsis: The National Institutes of Health (NIH) and the Centers for Disease Control and Prevention (CDC) hereby notify Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) holding specific types of research grants (activity codes listed above) that funds are available for administrative supplements to improve the diversity of the research workforce by recruiting and supporting students, postdoctorates, and eligible investigators from groups that have been shown to be underrepresented in health-related research. Administrative supplements must support work within the scope of the original project.

Application Receipt/Submission Date(s): Due dates may vary by awarding IC.

- **TITLE:** End-of-Life and Palliative Needs of Adolescents and Young Adults (AYA) with Serious Illnesses (R01) (PA-15-324)
  - **SPONSOR:** National Institute of Nursing Research, National Cancer Institute, Eunice Kennedy Shriver National Institute of Child Health and Human Development, Office of Research on Women's Health
  - **Synopsis:** The purpose of this funding opportunity announcement (FOA) is to foster research on the unique perspectives, needs, wishes, and decision-making processes of adolescents and young adults (AYA; defined by the World Health Organization and the Centers for Disease Control and Prevention as youth between 12 – 24 years of age) with serious, advanced illnesses; and research focused on specific end-of-life/palliative care (EOLPC) models that support the physical, psychological, spiritual, and social needs of AYA with serious illness, their families and caregivers.
  - **Application Receipt/Submission Date(s):** Multiple dates, see announcement.

- **TITLE:** End-of-Life and Palliative Needs of Adolescents and Young Adults (AYA) with Serious Illnesses (R21) (PA-15-325)
  - **SPONSOR:** National Institute of Nursing Research, National Cancer Institute, Eunice Kennedy Shriver National Institute of Child Health and Human Development, Office of Research on Women's Health
  - **Synopsis:** The purpose of this funding opportunity announcement (FOA) is to foster research on the unique perspectives, needs, wishes, and decision-making processes of adolescents and young adults (AYA; defined by the World Health Organization and the Centers for Disease Control and Prevention as youth between 12 – 24 years of age) with serious, advanced illnesses; and research focused on specific end-of-life/palliative care (EOLPC) models that support the physical, psychological, spiritual, and social needs of AYA with serious illness, their families and caregivers.
  - **Application Receipt/Submission Date(s):** Multiple dates, see announcement.

- **TITLE:** Time-Sensitive Obesity Policy and Program Evaluation (R01) (PAR-12-257)
  - **SPONSOR:** National Institute of Diabetes and Digestive and Kidney Diseases, National Institute on Aging, National Cancer Institute, Eunice Kennedy Shriver National Institute of Child Health and Human Development, Office of Behavioral and Social Sciences Research
  - **Synopsis:** All applications to this FOA must demonstrate that the evaluation of an obesity related policy and/or program offers an uncommon and scientifically compelling research opportunity that will only be available if the research is initiated with minimum delay. For these reasons, applications in response to this time-sensitive FOA are eligible for only one submission. It is intended that eligible applications selected for funding will be awarded within 3-4 months after the application submission/receipt date. However, administrative requirements and other unforeseen circumstances may delay issuance dates beyond that timeline.
  - **Application Receipt/Submission Date(s):** Multiple dates, see announcement.

- **TITLE:** NCI Exploratory/Developmental Research Grant Program (NCI Omnibus R21) (PAR-15-340)
  - **SPONSOR:** National Cancer Institute
  - **Synopsis:** The National Cancer Institute (NCI) Exploratory/Developmental Grant (R21) funding opportunity supports the development of new research activities in all areas of cancer research. The R21 mechanism is intended to encourage exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to a breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of cancer research (biomedical, behavioral, or clinical).
  - **Application Receipt/Submission Date(s):** November 10, 2015.

- **TITLE:** NCI Outstanding Investigator Award (R35) (PAR-15-342)
  - **SPONSOR:** National Cancer Institute
  - **Synopsis:** This Funding Opportunity Announcement (FOA) invites grant applications for the Outstanding Investigator Award (R35) in any area of cancer research. The objective of the National Cancer Institute (NCI) Outstanding Investigator Award (OIA) is to provide long-term support to accomplished investigators with outstanding records of cancer research productivity who propose to conduct exceptional research. The OIA is intended to allow investigators the opportunity to take greater risks, be more adventurous in their lines of inquiry, or take the time to develop new
TITLE: NCI Mentored Research Scientist Development Award to Promote Diversity (K01)  
(PAR-15-064)  
SPONSOR: National Cancer Institute  
Synopsis: The purpose of the NCI Mentored Research Scientist Development Award (K01) is to enhance the diversity of the NCI-funded cancer research workforce by supporting eligible individuals from groups that have been shown to be underrepresented in the biomedical, behavioral, social and clinical sciences. This FOA provides salary and research support for a sustained period of "protected time" for intensive research career development under the guidance of an experienced mentor, or sponsor. The Diversity Training Branch (DTB) of the Center to Reduce Cancer Health Disparities (CRCHD), at the National Cancer Institute (NCI), invites career development award applications (K01) from individuals from backgrounds that have been shown to be underrepresented in health-related science.  
Application Receipt/Submission Date(s): Multiple dates, see announcement.

TITLE: Advancing Interventions to Improve Medication Adherence (R01)  
(PA-14-334)  
SPONSOR: National Cancer Institute  
Synopsis: This funding opportunity announcement (FOA) is being issued by the NIH Adherence Network through the Office of Behavioral and Social Sciences Research (OBSSR), with participation from multiple NIH Institutes and Centers. This FOA seeks Research Project Grant (R01) applications that propose interventions to significantly improve medication adherence in individuals. Applications may target medication adherence in the context of treatment for a single illness or chronic condition (e.g., hypertension), to stave off a disease recurrence (e.g., cancer) or for multiple comorbid conditions (e.g., hypertension, diabetes, alcohol use disorders and HIV/AIDS). A well-articulated theoretical or conceptual framework is key for applications encouraged under this announcement. Primary outcomes of the research can include a patient self-report of medication adherence, but must also at least one non-self-report measure of medication adherence (e.g., pharmacy refill records, electronic monitoring, etc.). In addition, applications are encouraged to include a relevant health outcome or biomarker (e.g., blood pressure, viral load in HIV-infected individuals, cholesterol levels, HbA1c) that is expected to be affected by changes in the targeted adherence behavior. For diseases without identified biomarkers, inclusion of a clinical assessment (e.g., a medicine blood level, diagnostic interview or an independent clinician rating of the symptoms and behaviors) may be considered.  
Application Receipt/Submission Date(s): Multiple dates, see announcement.

TITLE: Advancing Interventions to Improve Medication Adherence (R21)  
(PA-14-335)  
SPONSOR: Office of Behavioral and Social Sciences Research, National Eye Institute, National Heart, Lung, and Blood Institute, National Institute on Alcohol Abuse and Alcoholism, National Institute on Deafness and Other Communication Disorders, National Institute of Mental Health, National Institute of Nursing Research, National Cancer Institute  
Synopsis: This funding opportunity announcement (FOA) is being issued by the NIH Adherence Network through the Office of Behavioral and Social Sciences Research (OBSSR), with participation from multiple NIH Institutes and Centers. This FOA seeks Research Project Grant (R01) applications that propose interventions to significantly improve medication adherence in individuals. Applications may target medication adherence in the context of treatment for a single illness or chronic condition (e.g., hypertension), to stave off a disease recurrence (e.g., cancer) or for multiple comorbid conditions (e.g., hypertension, diabetes, alcohol use disorders and HIV/AIDS). A well-articulated theoretical or conceptual framework is key for applications encouraged under this announcement. Primary outcomes of the research can include a patient self-report of medication adherence, but must also at least one non-self-report measure of medication adherence (e.g., pharmacy refill records, electronic monitoring, etc.). In addition, applications are encouraged to include a relevant health outcome or biomarker (e.g., blood pressure, viral load in HIV-infected individuals, cholesterol levels, HbA1c) that is expected to be affected by changes in the targeted adherence behavior. For diseases without identified biomarkers, inclusion of a clinical assessment (e.g., a medicine blood level, diagnostic interview or an independent clinician rating of the symptoms and behaviors) may be considered.  
Application Receipt/Submission Date(s): Multiple dates, see announcement.

TITLE: Advancing the Science of Geriatric Palliative Care (R03)  
(PA-13-356)  
SPONSOR: National Institute of Aging, National Cancer Institute  
Synopsis: This Funding Opportunity Announcement (FOA) encourages research grant applications focused on palliative care in geriatric populations. This R03 announcement specifically encourages projects primarily aimed at collection of pilot data, demonstration of feasibility, development of new methodology, or other goals of limited scope requiring short-term support. This FOA emphasizes studies in a variety of settings including ambulatory care, hospitals (and specific sites within hospitals including specialty wards, intensive care units and emergency techniques. The OIA would allow an Institution to submit applications nominating established Program Directors/Principal Investigators (PDs/PIs) for 7-year grants. It is expected that the OIA would provide extended funding stability and encourage investigators to embark on projects of unusual potential in cancer research. The research projects should break new ground or extend previous discoveries toward new directions or applications that may lead to a breakthrough that will advance biomedical, behavioral, or clinical cancer research.  
Application Receipt/Submission Date(s): November 23, 2015.
departments), assisted living facilities, and short- and long-term care facilities; however, hospice and end-of-life settings are not included within the scope of this FOA, as they are the subject of other NIH programs. Rather, this FOA highlights research on palliative care in settings and at time points earlier in geriatric patients’ disease or disability trajectories. Types of studies may include observational, quasi-experimental, or pilot interventional studies using primary data collection and/or secondary analyses. Leveraging on-going cohorts, intervention studies, networks, data and specimen repositories, and other existing resources and infrastructure are encouraged.

**TITLE: Advancing the Science of Geriatric Palliative Care (R01)**
(PA-13-354)
**SPONSOR:** National Institute of Aging, National Institute of Nursing Research, National Center for Complementary and Integrative Health, National Cancer Institute
**Synopsis:** This Funding Opportunity Announcement (FOA) encourages research grant applications focused on palliative care in geriatric populations. This FOA emphasizes studies in a variety of settings including ambulatory care, hospitals (and specific sites within hospitals including specialty wards, intensive care units and emergency departments), assisted living facilities, and short- and long-term care facilities; however, hospice and end-of-life settings are not included within the scope of this FOA, as they are the subject of other NIH programs. Rather, this FOA highlights research on palliative care in settings and at time points earlier in geriatric patients’ disease or disability trajectories. Types of studies may include observational, quasi-experimental, or interventional studies using primary data collection and/or secondary analyses. Leveraging on-going cohorts, intervention studies, networks, data and specimen repositories, and other existing resources and infrastructure are encouraged.

**TITLE: Advancing the Science of Geriatric Palliative Care (R21)**
(PA-13-355)
**SPONSOR:** National Institute of Aging, National Institute of Nursing Research, **National Cancer Institute**
**Synopsis:** This Funding Opportunity Announcement (FOA) encourages research grant applications focused on palliative care in geriatric populations. This FOA emphasizes studies in a variety of settings including ambulatory care, hospitals (and specific sites within hospitals including specialty wards, intensive care units and emergency departments), assisted living facilities, and short- and long-term care facilities; however, hospice and end-of-life settings are not included within the scope of this FOA, as they are the subject of other NIH programs. Rather, this FOA highlights research on palliative care in settings and at time points earlier in geriatric patients’ disease or disability trajectories. Types of studies may include observational, quasi-experimental, or interventional studies using primary data collection and/or secondary analyses. Leveraging on-going cohorts, intervention studies, networks, data and specimen repositories, and other existing resources and infrastructure are encouraged.

**TITLE: AHRQ Grants for Health Services Research Dissertation Program (R36)**
(PA-15-318)
**SPONSOR:** Agency for Healthcare Research and Quality
**Synopsis:**

**TITLE: Collaborative Activities to Promote Metabolomics Research (Admin Supp)**
(PAR-13-374)
**SPONSOR:** United States Department of Health and Human Services, National Cancer Institute
**Synopsis:** This FOA supports supplemental funds to current NIH-funded research projects for new interactive collaborations between basic or clinical researchers and metabolomics experts to add a metabolomics approach to the existing Research Strategy for the project. In addition to enhancing the parent grant by adding metabolomics analyses, collaborative projects must include activities to increase the expertise of the biomedical research group in key aspects of metabolomics study design, analysis, and data interpretation. All applicants are strongly encouraged to discuss potential requests with the awarding IC and with the Common Fund Metabolomics Scientific/Research contact listed below.

**TITLE: Ruth L. Kirschstein National Research Service Award (NRSA) Institutional Research Training Grants (Parent T32)**
(PA-14-015)
**SPONSOR:** Department of Health and Human Services
**Synopsis:**

**TITLE: Spatial Uncertainty: Data, Modeling, and Communication (R03)**
(PA-15-011)
**SPONSOR:** Department of Health and Human Services
**Synopsis:**
Spatial Uncertainty: Data, Modeling, and Communication (R21)
(ROI-15-009)
SPONSOR: Department of Health and Human Services
Application Receipt/Submission Date(s): Multiple dates, see announcement.

TITLE: High Throughput Screening (HTS) to Discover Chemical Probes (R21)
(ROI-14-283)
SPONSOR: Department of Health and Human Services
Application Receipt/Submission Date(s): Multiple dates, see announcement.

TITLE: Modeling Social Behavior (R01)
SPONSOR: Department of Health and Human Services, National Institutes of Health
(ROI-13-374)
Application Receipt/Submission Date(s): Multiple dates, see announcement.

TITLE: Examination of Survivorship Care Planning Efficacy and Impact (R21)
(ROI-16-011)
SPONSOR: National Cancer Institute
Synopsis: The purpose of this Funding Opportunity Announcement (FOA) is to stimulate developmental research evaluating the effect of care planning on self-management of late effects of cancer therapy; adherence to medications, cancer screening, and health behavior guidelines; utilization of follow-up care; survivors' health and psychosocial outcomes. How organizational-level factors influence the implementation of care planning and its associated costs is also of interest. Specifically, the FOA aims to stimulate research that will: 1) develop and test metrics for evaluating the impact of survivorship care planning; 2) evaluate the impact of survivorship care planning on cancer survivors' morbidity, self-management and adherence to care recommendations, utilization of follow-up care; 3) evaluate effects of planning on systems outcomes, such as associated costs and impact on providers and organizations implementing the care planning; and 4) identify models and processes of care that promote effective survivorship care planning. The ultimate goal of this FOA is to generate a body of science that will inform the development and delivery of interventions that improve follow-up care for cancer survivors.
Application Receipt/Submission Date(s): Multiple dates, see announcement.

TITLE: Examination of Survivorship Care Planning Efficacy and Impact (R01)
(ROI-16-012)
SPONSOR: National Cancer Institute
Synopsis: The purpose of this Funding Opportunity Announcement (FOA) is to stimulate research evaluating the effect of care planning on self-management of late effects of cancer therapy; adherence to medications, cancer screening, and health behavior guidelines; utilization of follow-up care; survivors' health and psychosocial outcomes. How organizational-level factors influence the implementation of care planning and its associated costs is also of interest. Specifically, the FOA aims to stimulate research that will: 1) develop and test metrics for evaluating the impact of survivorship care planning; 2) evaluate the impact of survivorship care planning on cancer survivors' morbidity, self-management and adherence to care recommendations, utilization of follow-up care; 3) evaluate effects of planning on systems outcomes, such as associated costs and impact on providers and organizations implementing the care planning; and 4) identify models and processes of care that promote effective survivorship care planning. The ultimate goal of this FOA is to generate a body of science that will inform the development and delivery of interventions that improve follow-up care for cancer survivors.
Application Receipt/Submission Date(s): Multiple dates, see announcement.

OTHER FUNDING OPPORTUNITIES
(Sponsors in bold are NIH Peer Reviewed Organizations)

TITLE: Cancer Control Career Development Awards for Primary Care Physicians (CCDA)
SPONSOR: American Cancer Society

TITLE: Grants and Prizes
http://www.foundationforwomenscancer.org/research-opportunities/current-year-research-grants-and-prizes/
SPONSOR: Foundation for Women's Cancer

TITLE: Doctoral Degree Scholarships in Cancer Nursing
SPONSOR: American Cancer Society

TITLE: Pilot and Exploratory Projects in Palliative Care of Cancer Patients and Their Families
SPONSOR: American Cancer Society
SPONSOR: American Cancer Society

- TITLE: Doctoral Training Grants in Oncology Social Work
  http://www.cancer.org/research/applyforaresearchgrant/granttypes/doctoral-training-grant-oncology-social-work
  SPONSOR: American Cancer Society

- TITLE: Mentored Training and Career Development Grants: Master's Training Grants in Clinical Oncology Social Work
  SPONSOR: American Cancer Society

- TITLE: The Avon Breast Health Outreach Program
  https://app.trialect.com/2013/display
  SPONSOR: The Avon Foundation for Women

- TITLE: Research Grants
  http://terribrodeurbreastcancerfoundation.org/granting-process/
  SPONSOR: Terri Brodeur Breast Cancer Foundation

- TITLE: Blavatnik Awards for Young Scientists: National Competition
  http://blavatnikawards.org/awards/national-awards/nomination-guidelines/
  SPONSOR: New York Academy of Sciences

- TITLE: Request For Proposals: Special Opportunity
  http://www.curemelanoma.org/research/request-for-proposals/
  SPONSOR: Melanoma Research Alliance

- TITLE: 2015 Investigator's Award in Clinical Translation of Cell and Gene Therapy for Sarcoma
  https://proposalcentral.altum.com/Login.asp
  SPONSOR: Alliance for Cancer Gene Therapy

- TITLE: Clinic and Laboratory Integration Program (CLIP) Grants
  SPONSOR: Cancer Research Institute